Sonnet Biotherapeutics Shareholders Approve Merger with Hyperliquid Strategies
Sonnet Biotherapeutics shareholders approved a business combination with Hyperliquid Strategies on Dec. 2, market reports show. Hyperliquid Strategies previously announced plans to raise up to $1 billion to purchase HYPE and other assets.